Connection

Stefano Rusconi to Drug Therapy, Combination

Back to Details
This is a "connection" page, showing publications Stefano Rusconi has written about Drug Therapy, Combination.
Stefano Rusconi
Connection Strength
0.204
Drug Therapy, Combination
  1. Clinical pharmacology in HIV cure research - what impact have we seen? Expert Rev Clin Pharmacol. 2019 Jan; 12(1):17-29.
    View in: PubMed
    Score: 0.070
  2. Impact of NRTI resistance mutations on virological effectiveness of antiretroviral regimens containing elvitegravir: a multi-cohort study. J Antimicrob Chemother. 2020 01 01; 75(1):194-199.
    View in: PubMed
    Score: 0.019
  3. Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapy. BMC Infect Dis. 2018 Nov 12; 18(1):556.
    View in: PubMed
    Score: 0.017
  4. Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial. J Antimicrob Chemother. 2018 07 01; 73(7):1955-1964.
    View in: PubMed
    Score: 0.017
  5. Dolutegravir Plus Rilpivirine as a Switch Option in cART-Experienced Patients: 96-Week Data. Ann Pharmacother. 2018 08; 52(8):740-746.
    View in: PubMed
    Score: 0.017
  6. Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial. PLoS One. 2017; 12(11):e0187393.
    View in: PubMed
    Score: 0.016
  7. A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks' observational data. BMC Infect Dis. 2017 09 30; 17(1):658.
    View in: PubMed
    Score: 0.016
  8. Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA =50 cp/mL. Infection. 2017 Aug; 45(4):521-528.
    View in: PubMed
    Score: 0.016
  9. Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M). J Antimicrob Chemother. 2017 04 01; 72(4):1163-1171.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.